The Biopharmaceutical Industry is Tracking and Researching COVID-19 Variants

From The Catalyst

The biopharmaceutical industry is committed to developing solutions to help diagnose, treat and prevent COVID-19. Across the industry, companies are tracking emerging variants using genomic surveillance to identify and decode changes in the virus, as well as further continuing clinical research to assess whether modifications or boosters are warranted to existing vaccines to address emerging variants. To learn more about the latest developments in new vaccines and treatments, read this fact sheet.